Introduction
Determination of the etiology of biliary strictures represents a significant challenge
despite advances in endoscopic techniques. Taking into account both the aggressive
behavior of pancreatobiliary neoplasms and the significant morbidity and mortality
of pancreatobiliary surgery [1 ]
[2 ], the correct distinction between a benign and malignant biliary stricture is of
crucial importance. It has, indeed, been reported that two-thirds of indeterminate
biliary strictures are malignant, but one-fourth of all surgical resection specimens
for this indication were reported as benign disease [3 ]
[4 ].
Many underlying diseases may cause biliary strictures, including malignancies (cholangiocarcinoma
or pancreatic cancer in the majority of cases) and also benign disorders such as autoimmune
processes (primary sclerosing cholangitis, immunoglobulin (Ig)G4-related cholangitis,
autoimmune pancreatitis), vascular injuries, and infectious diseases. Biliary strictures
also can be the sequelae of iatrogenic or non-iatrogenic trauma (eg, post-cholecystectomy
or long-standing choledocholithiasis) [5 ]. Most the time, distinguishing between these different etiologies is extremely cumbersome.
Moreover, in case of locally advanced cancer, when the malignant etiology can be easily
deducted, pathological proof is still necessary to plan chemotherapy.
Despite being considered a therapeutic technique, endoscopic retrograde cholangiopancreatography
(ERCP) still has a prominent diagnostic role in patients with biliary strictures,
especially when there is no evidence of mass lesion. Biliary stricture brushing is
considered the safest, easiest, cheapest, and fastest way to acquire a cytological
specimen from the biliary tree for diagnosing the etiology of a stricture, but despite
a specificity of 99 % to 100 %, the sensitivity is only around 45 % [6 ]. Additional techniques can increase this sensitivity. Fluorescence in situ hybridization
(FISH)-chromosomal aneuploidy on brushing specimen or on bile aspirate has a sensitivity
of 34 % to 52 % [7 ], the use of optical coherence tomography (OCT) on the bile duct has a sensitivity
of 53 % [7 ]
[8 ], and combined use of cytology, FISH, and mutation profiling has been reported to
increase sensitivity up to 69 % [9 ].
Considering these figures, in the past few years, the field has moved toward acquisition
of histological samples, with use of biopsy forceps, which have to be carefully guided
to the site of the stricture. Therefore, cholangioscopes and cholangioscopy-directed
biopsy have been developed, achieving a sensitivity of 71.9 % [10 ] despite heterogeneous results, with new evidence suggesting a lower diagnostic yield
[11 ].
Rapid on-site evaluation (ROSE) of the cytological sample has been used for years
for determination of adequacy of endoscopic ultrasonography-guided fine needle aspiration
(EUS-FNA) cytological specimens, improving its sensitivity and specificity [12 ]. Nevertheless, to the best of our knowledge, no studies have investigated the role
of ROSE for ERCP-guided brushing.
The aim of our study, therefore, was to evaluate the diagnostic yield of the ERCP-guided
brushing in determining the etiology of biliary strictures when supported by ROSE.
Patients and methods
Study design and population
A retrospective single-center study was conducted at IRCCS San Raffaele Hospital and
enrolled patients undergoing ERCP for biliary strictures with a brushing technique
supported by ROSE (IRB approval “Protocollo Registro ERCP 06/02/2014”).
Data from all consecutive patients who had undergone ERCP with the brushing technique
over an 11-year period (October 2008–October 2019) were retrieved from an electronic
database in which information on the following variables was prospectively recorded:
patient characteristics such as gender, age, presenting symptom, reports of computed
tomography (CT) or magnetic resonance imaging (MRI) or EUS, whether the stricture
was identified or not, site of the stricture, evidence of mass-lesion, indication
for the ERCP procedure, procedure technical details including stricture location at
ERCP cholangiography, brushing features such as number of passages to achieve adequacy,
presence of a biliary stent (plastic or metallic) before the ERCP procedure, execution
of bile duct biopsies during ERCP procedure, execution of follow-up through ERCP,
use of confocal laser endomicroscopy (CLE), cholangioscopy, dilation of the stricture,
execution of surgery, and final pathology. The same electronic database was used to
retrieve data on patient follow-up.
The study population was selected to include patients undergoing ERCP with execution
of brushing for the first time in the biliary tract, supported by ROSE.
Exclusion criteria were: 1. patients undergoing ERCP with brushing on the pancreatic
duct; 2. patients undergoing brushing without the support of ROSE; 3. evidence of
bile duct stricture due to liver hilum lymphadenopathies; 4. absence of follow-up
of at least 6 months or final histopathological diagnosis; and 5. patients undergoing
a second session of ERCP with brushing (we considered only patients undergoing ERCP
with brushing for the first time).
Procedure description and specimen processing
ERCP procedures were performed under deep sedation with intravenous infusion of propofol
(Diprivan, Zeneca, Germany), using Pentax duodenoscopes (ED3470TK, ED34i10 T), by
expert endoscopists who had performed over 200 procedures per year. Written informed
consent was obtained from each included patient before the procedure.
During the procedure, biliary strictures were identified on cholangiography using
Iopamidol (Iopamiro, Bracco, Italy) contrast agent, and a cytopathological specimen
was obtained using the Cytology Brush (Cook Medical, United States) or RX Cytology
Brush (Boston Scientific, United States), with a non-standardized number of brush
passages defined arbitrarily until sample adequacy was obtained at ROSE. Specifically,
after a first passage, the endoscopist would wait for the response regarding the adequacy
to either perform additional passages until adequacy was obtained or move on to forceps
biopsy or stent positioning.
The brushing specimen was processed for ROSE by an onsite cytopathologist or cytotechnician,
with the smears prepared immediately after obtaining the specimen by gently pressing
and scraping the brush onto a clean glass slide to exfoliate the cells on it. At least
two slides smears were prepared in each case, which were fixed in absolute alcohol
and stained with a rapid 2-minute hematoxylin-eosin stain. Once the slides were prepared,
they were examined by an onsite cytopathologist and real-time evaluation of the sample
adequacy was performed. A sample was considered adequate based on whether there was
enough material representative of the site of sampling, independent of whether it
was deemed benign or malignant and irrespective of clinical suspicion. A diagnostic
category was provided, depending upon whether the nature of the cells was benign (when
the cytologic specimen did not reveal malignancy), suspicious, or malignant. The diagnosis
was based on classic cytologic criteria, i.e nuclear shape and dimension, hyperchromasia,
high nuclear-to-cytoplasmic ratio, cyto-architectural abnormalities, and necrotic
background. The onsite cytopathologist was not blinded to patient clinical and radiological
history.
A forceps biopsy could be performed in cases of adequate location and conformation
of the stricture, based on endoscopist preference and always after at least a first
brush passage.
Subsequent ERCP sessions were performed on patients with indeterminate diagnosis both
to repeat the brushing, perform biopsies or study the stricture with the cholangioscope,
or to exchange the plastic stent in place.
Definition of the gold-standard and other definitions
A case was considered as “true positive” when, after a cytologic diagnosis suspicious
for malignancy or of malignancy on ROSE, the patient was found to have a malignant
stricture. The definition of malignancy was based on a final histopathological diagnosis
on a surgical sample from patients who had undergone surgery and evidence of malignancy
on histopathological evaluation of the specimen from forceps biopsy or in patients
who did not undergo surgery, on an EUS-FNA sample performed on the stricture or evidence
of progression of the disease after at least 6 months of follow-up (onset of liver
or peritoneal metastases or growth of the mass lesion with evidence of vascular infiltration
if not present at baseline).
A case was considered as “true negative” when, after a benign cytologic diagnosis
on ROSE, the patient was found to have a benign stricture as defined by a final histopathological
diagnosis based on a surgical sample in patients who underwent surgery and evidence
of stability or disappearance of the stricture after at least 6 months of follow-up
in patients who did not undergo surgery.
In cases in which baseline CT scan, MRI or EUS revealed the presence of a solid mass-forming
stricture of the bile duct (arising either from the pancreas or from any tract of
the bile duct) and not just a thickening of bile duct walls, the case was considered
as being a “mass-forming” disease.
Statistical analysis
Descriptive statistics were calculated as means and standard deviation (SD) for normally
distributed continuous variables, as means and SD and median and interquartile range
(IQR) for continuous variables with skewed distribution, and as numbers and percentages
for categorical variables.
A paired Student’s t -test was employed for comparison of normally distributed continuous variables, a
Mann-Whitney U test was used for continuous variables with skewed distribution, and
Fisher’s exact test was employed for the comparison of categorical variables.
Accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive
value (NPV) for ERCP-guided brushing plus ROSE diagnosis were calculated. A receiver
operating characteristic (ROC) curve was then plotted and area under the curve (AUC)
calculated.
After evaluation of the diagnostic yield of ROSE, characteristics of true-positive
and false-negative cases were compared. All calculations were performed using MedCalc
version 13 (MedCalc Software, Belgium). P < 0.05 was considered statistically significant.
The “Standards for Reporting Diagnostic accuracy studies” (STARD) and “STrengthening
the Reporting of OBservational studies in Epidemiology” (STROBE) checklists were checked
for items that should be included in the report.
Results
Patients and biliary stricture characteristics
Of 5,929 ERCP procedures performed between October 2008 and October 2019, 5,640 were
excluded, as reported in [Fig. 1 ]. The final number of patients included in the analysis was 206, 118 of whom were
male (57.3 %) with a median age at diagnosis of 72 years ([Table 1 ]).
Fig. 1 Flowchart of patient selection for ERCP-guided brushing supported by ROSE.
Table 1
Patient and biliary stricture characteristics.
Total patients enrolled (n = 206)
Age, years
69.2 (± 12.9)
72 (60–78)
Sex, male, n (%)
118 (57.3 %)
Dominant presenting symptom/sign
140 (68 %)
24 (11.6 %)
6 (2.9 %)
6 (2.9 %)
5 (2.4 %)
3 (1.4 %)
2 (0.9 %)
20 (9.7 %)
Location of the stricture
37 (18 %)
159 (77.2 %)
25 (12.1 %)
33 (16 %)
70 (34 %)
31 (15.1 %)
10 (4.8 %)
Final clinical/histological diagnosis of the strictures
79 (38.4 %)
11 (5.3 %)
23 (11.2 %)
13 (6.3 %)
5 (2.4 %)
75 (36.4 %)
Mass forming
44 (21.4 %)
Arising on Primary Sclerosing Cholangitis
4 (1.9 %)
Presenting with stent at ERCP with brushing session
40 (19.4 %)
36 (17.5 %)
4 (1.9 %)
Number of brushing passages, mean (± SD)
2.6 (± 0.6)
SD, standard deviation; IQR, interquartile range; CBD, common bile duct; IgG, immunoglobulin
G; ERCP, endoscopic retrograde cholangiopancreatography.
1 Affecting more than one third of the CBD.
2 Affecting both the CBD and the peri-hilar or peri-hilar and intrahepatic ducts.
3 Hepatocellular carcinoma, neuroendocrine neoplasia, ampullary carcinoma, and intraductal
papillary mucinous neoplasm of the biliary tract.
The majority of patients presented with jaundice (68 %), with a stricture in the common
bile duct (77.2 %) and a mass-forming lesion in 21 % of cases.
Diagnostic yield of ERCP-guided brushing supported by ROSE in establishing the etiology
of the biliary stricture
Overall, according to the aforementioned criteria, 126 patients (61.2 %) were deemed
to have a malignant stricture and 80 patients (38.8 %) a benign stricture. The outcome
(gold-standard) was defined in 67 cases (32.5 %) based on surgical resection (whether
benign or malignant at histopathological examination) in 24 (11.7 %) and 15 (7.3 %)
cases based on the malignant result of intraductal biopsy and EUS-FNA, respectively.
In the remaining cases, the outcome was defined based on evidence of progressive disease
or stable/remitted disease at a mean follow-up time of 40.8 months (median 26.5 months)
([Table 2 ]).
Table 2
Assessment of outcome through surgery, biopsy, EUS-FNA and follow-up.
Surgical resection
67 (32.5 %)[1 ]
9 (4.4 %)
58 (28.2 %)
Intraductal biopsy
44 (21.4 %)
20 (9.7 %)
24 (11.7 %)[1 ]
EUS-FNA
29 (14.1 %)
9 (4.4 %)
15 (7.3 %)[1 ]
5 (2.4 %)
Follow-up length of the remaining patients (months)
100 (48.5 %)[1 ]
40.8 ± 33.4
26.5 (15.5–64.8)
29 (14.1 %)
71 (34.4 %)
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; SD, standard deviation;
IQR, interquartile range.
1 Used as gold-standard
Ninety-eight percent of patients (203 of 206) had an adequate sample at ROSE ([Fig. 2 ]) after a mean number of passages of 2.6 (± 0.6)(range 1–4) ([Table 1 ]); the 2 % (3 cases) with non-adequate samples underwent a mean number of brush passages
of three.
Fig. 2 Brushing sample adequate for malignancy, with enlarged hyperchromatic nuclei, high
nuclear-to-cytoplasmic ratio, and necrotic background.
The diagnostic accuracy of ERCP-guided brushing with ROSE in determining the correct
etiology of biliary strictures was 83.5 %. Sensitivity and specificity were 74.6 %
and 97.5 %, respectively ([Table 3 ]), with an AUC of 0.86 ([Fig. 3 ]). PPV and NPV were 97.9 % and 70.9 %, respectively. Of the nine benign strictures
treated with surgical resection, four had a post-flogistic stricture (2 of them undergoing
resection for stricture leading to multiple episodes of cholangitis that did not respond
to endoscopic treatments) and five had IgG4-related cholangitis.
Table 3
Diagnostic yield of ERCP-guided brushing supported by ROSE in establishing the etiology
of biliary strictures.
TP
TN
FP
FN
Accuracy
Sensitivity
Specificity
PPV
NPV
+LR
–LR
94
78
2
32
83.5 %
74.6 %
97.5 %
97.9 %
70.9 %
30
0.26
TP, true positive; TN, true negative; FP, false positive; FN, false negative; PPV,
positive predictive value; NPV, negative predictive value; +LR, positive likelihood
ratio; –LR, negative likelihood ratio.
Fig. 3 Receiver operating characteristic (ROC) curves and area under the curve (AUC) for
the accuracy of ERCP-guided brushing supported by ROSE in establishing biliary stricture
etiology. The AUC is 0.86.
Of the 206 patients, three underwent cholangioscopy, with a visual report of a benign
stricture in all cases (2 true-negative, 1 false-negative).
Accuracy for ≤ 2 brush passages was 90 % and for ≥ 3 passages, it was 82 %.
Analysis of factors associated with true-positive versus false-negative results and
number of passages in performance of ERCP-guided brushing supported by ROSE
To identify possible factors associated with true-positive/false-negative results,
a subanalysis comparing the two groups was performed. As shown in [Table 4 ], false-negative cases were affected less frequently by cholangiocarcinoma of the
bile duct (46.8 % vs 68 %; P = 0.04) and more often by pancreatic cancer (28.1 % vs 14.8 %; P = 0.01) and gallbladder cancer (18.7 % vs 5.3 %; P = 0.03). No significant differences were found in terms of age, gender, presenting
symptoms, stricture location, mass-forming disease, biliary stent presence before
the brushing (despite being double among the false negative cases), or mean number
of brush passages.
Table 4
Comparison of patient and lesion variables in true-positive and false-negative cases.
True-positive (n = 94)
False-negative (n = 32)
P value
Age (years), median (IQR)
72 (62.5–80)
73 (59.2–75.5)
0.27
Sex (M)
51 (54.2 %)
15 (46.9 %)
0.5
Presenting with jaundice
77 (81.9 %)
24 (75 %)
0.4
Location of the stricture
24 (25.5 %)
7 (21.9 %)
0.8
62 (66 %)
23 (71.9 %)
0.6
8 (8.5 %)
2 (6.3 %)
1
Mass forming
29 (30.9 %)
12 (37.5 %)
0.5
Presenting with plastic/metal stent
10 (10.6 %)
7 (21.9 %)
0.13
Brush passages, mean ± SD
2.5 ± 0.6
2.7 ± 0.6
0.11
Final malignant etiology
64 (68 %)
15 (46.8 %)
0.04
26 (27.6 %)
12 (37.5 %)
38 (40.4 %)
3 (9.3 %)
5 (5.3 %)
6 (18.7 %)
0.03
0
1 (3.1 %)
5 (5.3 %)
5 (15.6 %)
14 (14.8 %)
9 (28.1 %)
0.01
5 (5.3 %)
7 (21.9 %)
9 (9.5 %)
2 (6.2 %)
11 (11.7 %)
2 (6.2 %)
0.51
IQR, interquartile range; CBD, common bild duct; EUS, endoscopic ultrasound.
Patients who underwent ≤ 2 or ≥ 3 brushing passages were not statistically different
in terms of having a biliary stent in place at first procedure (100 % vs 94 %), having
mass forming disease (30 % vs 20 %), or location of stenosis (70 % vs 70.1 % with
an extrahepatic stenosis, 20 % vs 23.5 % with hilary stricture and 10 % vs 6.4 % with
an extrahepatic stricture).
Discussion
Correctly diagnosing the etiology of a biliary stricture remains challenging. ERCP-guided
brushing is the cheapest and easiest technique, but its sensitivity is disappointing
at around 45 % [6 ]. Therefore, the use of more expensive, complex, and invasive techniques, such as
cholangioscopy-guided biopsy with a sensitivity around 72 % [10 ], are increasingly being suggested and performed.
ROSE has been used for years to increase the diagnostic yield of EUS-FNA adequacy,
but its role has never been explored in the context of ERCP-guided brushing, where
it may also assist in immediate decision-making.
In the present study, the use of ROSE as support for ERCP-guided biliary brushing
was evaluated for the first time in a cohort of 206 patients, resulting in a sensitivity
of 74.6 % and a final AUC of 0.86. The mean number of brush passages to achieve adequacy
was 2.6.
These data seem very promising compared to the majority of techniques currently performed,
such as the addition of fluoroscopy-guided biopsy, with a sensitivity of 67.9 % [13 ], FISH, with a sensitivity of 44 % [9 ], use of digital single-operator cholangioscopy, with recent reports of a sensitivity
for visual interpretation ranging between 64 % [11 ] and 89.1 % [14 ], and for bile duct sampling under cholangioscopic guidance, with sensitivity ranging
between 15 % [11 ] and 69.8 % [14 ].
Data are extremely limited on application of ROSE in cases other than EUS-FNA. Ali
et al. [15 ] retrospectively investigated its role in touch imprint cytology (TIC) of biopsies
of intestinal luminal or pancreatobiliary lesions taken during ERCP with cholangioscopy.
In the 121 pancreatobiliary lesions, the resulting sensitivity was 97 %. However,
this high yield has to be viewed with caution, as the outcome definition used as gold
standard was based only on the final histopathological result of the biopsy. In the
present study, the outcomes used as gold-standard were not related to the final report
of the brushing itself, but we considered either the final histopathological diagnosis
based on other techniques (surgical resection, intraductal biopsies, EUS-FNA) or a
follow-up that was more than 3 years on average. Indeed, in the decision-making process,
the role of ROSE is far more relevant during EUS-FNA because of the higher risk of
complications associated with the higher number of passages compared to the remarkable
safety of ERCP-guided brushing. Nevertheless, because this is the first study on the
topic, identification of the mean number of passages needed to achieve an adequacy
can help guide centers in which the ROSE is not available and it also can support
endoscopists performing ERCP in decision-making about stent positioning.
As with any method, the definition of the proper target population for applying this
technique is crucial and can help guide physicians. Some malignant diseases can lead
to biliary strictures due to extraluminal compression, which are therefore expected
to lead to false-negative results from both brushing and biopsy specimens. These diseases
include pancreatic cancer, hepatocellular carcinoma or hepatic metastases, gallbladder
cancer, and metastatic adenopathies of the liver hilum [5 ]. For this reason, in the present study, we excluded patients with metastatic adenopathies
of the liver hilum and performed a subgroup analysis of false-negative and true-positive
cases to investigate the possible role of the specific malignancy type and of other
factors, such as the presence of a biliary stent before the procedure [16 ]. In this subgroup analysis, false-negative cases more often had a final diagnosis
of gallbladder or pancreatic cancer, and less often cholangiocarcinoma. In cholangiocarcinoma,
the peculiar growth of the tumour (periductal infiltrating or intraductal growing)
can make it more likely that with brushing, an adequate sample of malignant tissue
can be collected in cases with intraductal growing; the risk of false-negative results
is higher for periductal infiltrating cases [17 ]. Nevertheless, the type of growth of cholangiocarcinoma cannot be hypothesized based
on imaging findings and can only be deduced from a surgical specimen. Despite being
statistically insignificant, the presence of a biliary stent before brushing was more
prevalent in false-negative cases compared to true-positive cases (22 % vs 10 %),
suggesting that it might reduce the sensitivity of brushing. Age, gender, stricture
location, mass-forming disease or number of brush passages did not differ between
the two groups. In addition, a slightly higher number of passages was not associated
with higher accuracy, suggesting that the tumor growth pattern (intraductal vs periductal)
is a more relevant factor.
This study has some strengths. It was the first study evaluating the use of ROSE for
ERCP-guided brushing; the aim, inclusion, and exclusion criteria were clearly defined;
it had a large sample size; and the diagnostic yield was calculated with strictly
defined gold standards and with a long follow-up.
However, there are limitations such as the lack of a control group, the retrospective
part of the study, and the heterogeneous gold-standard, as not all patients underwent
surgical resection. Furthermore, ROSE often is not available; nevertheless, a 2016
survey demonstrated that 65 % of EUS centers have ROSE, 98 % in the United States
and 50 % in Europe and Asia, respectively [18 ]. In addition, the expertise of the pathologists in a high-volume referral center
may not be replicated in non-tertiary centers, thus the present results may not be
widely applicable. In fact, the accuracy of brushing is highly dependent upon processing
and evaluation of samples, which in turn differs among different centers. Another
possible limitation is selection bias, meaning that this cohort of patients undergoing
biliary brushing at our tertiary referral center is not fully representable of other
cohorts of patients with biliary strictures. Indeed, in our center, the majority of
patients would undergo EUS-FNA first, if it is possible to sampling the lesion. Therefore,
diagnosis would be achieved in a high percentage of patients before ERCP and they
would not undergo sampling with brushing. This also could have led to selection of
more complex cases in which EUS-FNA had failed (as in [Table 2 ], 14 % of patients already underwent EUS-FNA) and, therefore, performance of ROSE
for ERCP-guided brushing may be underestimated. It would be interesting to investigate
whether ROSE for ERCP-guided brushing has even higher accuracy in centers where EUS-FNA
is less readily available or is performed by operators with less expertise. Finally,
bile intraductal aspiration for collection of additional cytological material was
not performed; use of this technique before or after brushing could further increase
the diagnostic yield [16 ]
[19 ]
[20 ]
[21 ] and may deserve further investigation.
Given such limitations, the present results should be interpreted with caution and
acknowledgment that replication of them is needed. Nevertheless, we believe that further
prospective investigation is warranted of ERCP-guided brushing supported by ROSE as
a first approach to biliary strictures. The present results may, indeed, suggest that
an effort in training the Pathology Unit [22 ] could be far more cost-effective than use of advanced technology. A recent study
by Deprez et al. [23 ] investigated the economic impact of cholangioscopy for biliary strictures, reporting
a unit cost for ERCP with brushing of 1,699 € and 3,946 € for cholangioscopy-guided
biopsies. The authors concluded that because in the longer term upfront use of cholangioscopy
could lead to a reduction in need for repeat procedures, its upfront use might eventually
lead to significant cost reduction. Notably, in a recent study, Singhi et al. [24 ] evaluated use of a 28-gene next generation sequencing (NGS) panel on ERCP-guided
acquired pathological specimens from biliary strictures to evaluate its effectiveness
in improving the diagnostic sensitivity of commonly performed techniques. The use
of this panel on brushing specimens helped increase the sensitivity from 35 % to 77 %,
data comparable to ours, albeit with the higher cost of NGS. The use of ROSE to guide
brushing during a first session of ERCP for biliary strictures prolongs the procedure
by a few minutes compared to a standard ERCP with brushing and requires an on-site
cytopathologist, resulting in additional costs. However, it is likely that these costs
are well balanced by avoiding that of repeated ERCP with cholangioscopy and/or molecular
diagnostics. These hypotheses need to be confirmed with prospective head-to-head trials
that include cost-effectiveness analyses.
Conclusion
In conclusion, this was the first study on the role and diagnostic yield of ROSE for
ERCP-guided brushing of biliary strictures, with findings of very high sensitivity,
considering the safety, cheapness, rapidity, and simplicity of the technique. Further
prospective and controlled studies are recommended to determine whether ERCP-guided
brushing with the aid of ROSE can be considered as that first step for diagnosis of
the etiology of biliary strictures and reduce the need for multiple ERCP sessions
and use expensive adjunctive techniques.